TRANSFORM II
Research type
Research Study
Full title
TRANSFORMII: Sirolimus-coated balloon versus drug-eluting stent in native coronary vessels
IRAS ID
311297
Contact name
Sandeep Basavarajaiah
Contact email
Sponsor organisation
Fondazione Ricerca e Innovazione Cardiovascolare ETS
Clinicaltrials.gov Identifier
Duration of Study in the UK
7 years, 0 months, 28 days
Research summary
This study is international, multicentric, prospective, investigator-driven, open-label, randomized (1:1) clinical trial that observe and evaluate the efficacy, of Magic Touch SCB compared to one of the gold standard treatment for native vessel disease (everolimus-eluting stent, EES).
Both devices have CE marking certificates and meet European Union rules and regulations. They are both used for the treatment of narrowing in coronary arteries, in accord with current local clinical practice. This study will be carried out in order to verify that the Magic Touch SCB is at least as good as the everolimus-eluting DES (EES). The primary objective of the study is to verify the non-inferiority of Magic Touch SCB compared to everolimus-eluting DES (EES) in terms of TLF, a composite clinical endpoint, at 12 months.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
22/NW/0280
Date of REC Opinion
7 Oct 2022
REC opinion
Further Information Favourable Opinion